A. Fromont's Profile

Role	Title	Level	Year	L/R
🐬	Epidemiology of multiple sclerosis. E. Leray, Thibault Moreau, A. Fromont, G. Edan	8	2016	8 🐬
🐜	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. 30 auth. Mikael Cohen, E. Maillart, A. Tourbah, J. de Seze, S. Vukusic, D. Brassat, O. Anne, S. Wiertlewski, W. Camu, S. Courtois, A. Ruet, M. Debouverie, E. Le Page, O. Casez, O. Heinzlef, ... B. Stankoff, B. Bourre, G. Castelnovo, A. Rico, E. Berger, J. Camdessanche, G. Defer, P. Clavelou, Abdullatif Al Khedr, H. Zéphir, A. Fromont, C. Papeix, B. Brochet, J. Pelletier, C. Lebrun	7	2014	7 🐜
🦁	Geographic variations of multiple sclerosis in France. 13 auth. A. Fromont, C. Binquet, E. Sauleau, I. Fournel, A. Bellisario, J. Adnet, A. Weill, S. Vukusic, C. Confavreux, M. Debouverie, ... L. Clerc, C. Bonithon‐Kopp, T. Moreau	7	2010	7 🦁
🦁	Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. A. Fromont, J. Seze, M. Fleury, J. Maillefert, Thibault Moreau	6	2009	6 🦁
🐜	Epidemiology of stroke in Europe: Geographic and environmental differences 7 auth. Y. Béjot, I. Benatru, O. Rouaud, A. Fromont, J. Besancenot, T. Moreau, ... M. Giroud	6	2007	6 🐜
🐜	Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI. 105 auth. P. Roca, A. Attyé, L. Colas, A. Tucholka, P. Rubini, S. Cackowski, J. Ding, J. Budzik, F. Renard, S. Doyle, Emmanuel L Barbier, I. Bousaid, R. Casey, S. Vukusic, N. Lassau, ... S. Verclytte, F. Cotton, B. Brochet, J. de Seze, P. Douek, F. Guillemin, D. Laplaud, C. Lebrun-Frénay, L. Mansuy, T. Moreau, J. Olaiz, J. Pelletier, C. Rigaud‐Bully, B. Stankoff, R. Marignier, M. Debouverie, G. Edan, J. Ciron, A. Ruet, N. Collongues, C. Lubetzki, P. Vermersch, P. Labauge, G. Defer, M. Cohen, A. Fromont, S. Wiertlewsky, E. Berger, P. Clavelou, B. Audoin, C. Giannesini, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Créange, J. Camdessanche, J. Faure, A. Maurousset, I. Patry, K. Hankiewicz, C. Pottier, N. Maubeuge, C. Labeyrie, C. Nifle, R. Ameli, R. Anxionnat, E. Bannier, C. Barillot, D. Ben Salem, M. Boncoeur-Martel, F. Bonneville, C. Boutet, J. Brisset, F. Cervenanski, B. Claise, O. Commowick, J. Constans, P. Dardel, H. Desal, V. Dousset, F. Durand-Dubief, J. Ferré, E. Gerardin, T. Glattard, S. Grand, T. Grenier, R. Guillevin, C. Guttmann, A. Krainik, S. Kremer, S. Lion, N. Menjot de Champfleur, L. Mondot, O. Outteryck, N. Pyatigorskaya, J. Pruvo, S. Rabasté, J. Ranjeva, J. Roch, J. Sadik, D. Sappey-Marinier, J. Savatovsky, J. Tanguy, A. Tourbah, T. Tourdias	6	2020	6 🐜
🐜	Cancer and multiple sclerosis in the era of disease-modifying treatments 13 auth. C. Lebrun, P. Vermersch, D. Brassat, G. Defer, L. Rumbach, P. Clavelou, M. Debouverie, J. Seze, Sandrine Wiertlevsky, O. Heinzlef, ... A. Tourbah, A. Fromont, M. Frénay	5	2011	5 🐜
🦁	National estimate of multiple sclerosis incidence in France (2001–2007) 10 auth. A. Fromont, Christine Binquet, Erik Sauleau, Isabelle Fournel, R. Despalins, F. Rollot, ... Alain Weill, L. Clerc, C. Bonithon‐Kopp, Thibault Moreau	5	2012	5 🦁
🐜	Mitochondrial dysfunctions in 7-ketocholesterol-treated 158N oligodendrocytes without or with α-tocopherol: Impacts on the cellular profil of tricarboxylic cycle-associated organic acids, long chain saturated and unsaturated fatty acids, oxysterols, cholesterol and cholesterol precursors 10 auth. V. Leoni, T. Nury, A. Véjux, A. Zarrouk, C. Caccia, Meryam Debbabi, ... A. Fromont, R. Sghaier, T. Moreau, G. Lizard	5	2017	5 🐜
🐜	Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes 15 auth. A. Zarrouk, T. Nury, E. Karym, A. Véjux, R. Sghaier, C. Gondcaille, P. Andreoletti, D. Trompier, S. Savary, M. Cherkaoui‐Malki, ... Meryam Debbabi, A. Fromont, J. Riedinger, T. Moreau, G. Lizard	5	2017	5 🐜